Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord

• US 7,098,027 B2
• Filed: 12/23/2002
• Issued: 08/29/2006
• Est. Priority Date: 06/26/2000
• Status: Expired due to Term

• Current Assignee: NC Medical Research Inc. (e-solutions, Inc. /Japan/), Mitsui Sumitomo Insurance Care Network Co., Ltd. (Ms&Ad Insurance Group Holdings Incorporated)
• Original Assignee: ASKA Pharmaceutical Company Limited, Hitachi, Ltd., Mitsui Sumitomo Insurance Care Network Co., Ltd. (Ms&Ad Insurance Group Holdings Incorporated), Renomedix Institute, Inc.
• Inventors: Hashi, Kazuo, Uede, Teiji, Honmou, Osamu
• Primary Examiner(s): Saucier, Sandra E.
• Assistant Examiner(s): BARNHART, LORA ELIZABETH
• Application Number:
  US10/330,963
• Publication Number:
  US 20040121461A1
• Time in Patent Office: 1,345 Days
• Field of Search: 435/6, 435/325, 435/347, 435/355, 435/372
• US Class Current: 435/325
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2506/1353 from bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0622 Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
• CPC Class Codes: C12N 5/0662 Stem cells
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0664 Dental pulp stem cells, Dental follicle stem cells
• CPC Class Codes: C12N 5/0665 Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
• CPC Class Codes: C12N 5/0666 Mesenchymal stem cells from hair follicles
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/0668 : Mesenchymal stem cells from other natural sources
• CPC Class Codes: C12N 5/0676 : Pancreatic cells

Abstract

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

Claims

1. A method of remyelinating a demyelinized lesion due to injury in the brain or spinal cord of a patient, comprising

obtaining bone marrow cells from the patient,

diluting the bone marrow cells,

centrifuging the bone marrow cells, thereby separating a mononuclear cell fraction having a specific gravity of 1.07 to 1.1 g/mL,

collecting said mononuclear cell fraction,

suspending said mononuclear cell fraction in a serum-free medium to form a suspension,

centrifuging said suspension to yield a centrifuged mononuclear cell fraction and a supernatant,

removing said supernatant from the centrifuged mononuclear cell fraction,

resuspending said centrifuged mononuclear cell fraction in a serum-free medium, thereby forming a resulting mononuclear cell fraction, and

injecting said resulting mononuclear cell fraction directly into the lesion in the patient,

whereby the injected mononuclear cell fraction migrates to neural tissue in the patient, differentiates into neural cells, and forms myelinated axons in the demyelinated lesion three weeks after injection.

2. The method of claim 1, wherein the lesion is in the spinal cord, and remyelination occurs across the spinal cord'"'"'s dorsal column.